2024 ESC Guidelines for the management of atrial fibrillation
This guideline cites 19 of the 199 landmark trials in our Cardiology register.
- Issued by
- ESC
- Year
- 2024
- Source
- Van Gelder IC, Rienstra M, et al. Eur Heart J. 2024;45(36):3314–3414.doi 10.1093/eurheartj/ehae176
The 2024 ESC AF guideline reframes care around the AF-CARE pathway ([C]omorbidity and risk-factor management, [A]void stroke and thromboembolism, [R]educe symptoms by rate and rhythm control, [E]valuation and dynamic reassessment) and simplifies stroke risk to the sex-neutral CHA₂DS₂-VA score. The register's landmark AF trials are grouped below by AF-CARE theme.
Avoid stroke: anticoagulation6
- 2024FRAIL-AFCardiology · AF · DOAC switchIn 1,330 frail elderly patients with atrial fibrillation stable on a vitamin K antagonist, switching to a DOAC increased major or clinically relevant bleeding compared with continuing the vitamin K antagonist.HR 1.6995% CI 1.23-2.32Read →
- 2013ENGAGE AF-TIMI 48Cardiology · AF · AnticoagulationIn 21,105 patients with AF at moderate-to-high stroke risk, edoxaban was non-inferior to warfarin for stroke or systemic embolism, with less bleeding.Read →
- 2011ROCKET-AFCardiology · AF · AnticoagulationIn 14,264 patients with non-valvular AF at moderate-high stroke risk, rivaroxaban was non-inferior to warfarin for stroke or systemic embolism, with less intracranial bleeding.Read →
- 2011ARISTOTLE CoreCardiology · AF · AnticoagulationIn 18,201 patients with AF and ≥ 1 stroke risk factor, apixaban reduced stroke or systemic embolism, major bleeding and all-cause mortality compared with warfarin.Read →
- 2009RE-LY CoreCardiology · AF · AnticoagulationIn 18,113 patients with non-valvular AF, dabigatran 150 mg twice daily reduced stroke or systemic embolism compared with warfarin, with similar major bleeding.RR 0.66Read →
- 1991SPAFCardiology · AF · antithromboticIn 1,330 patients with non-rheumatic atrial fibrillation, warfarin and aspirin each reduced ischaemic stroke or systemic embolism compared with placebo.Read →
Reduce symptoms: rate vs. early rhythm control6
- 2021EARLY-AFCardiology · AF · AblationIn 303 patients with paroxysmal AF, first-line cryoballoon ablation reduced atrial arrhythmia recurrence compared with antiarrhythmic drugs.HR 0.48Read →
- 2020EAST-AFNET 4Cardiology · AF · Rate vs rhythmIn 2,789 patients with early AF (≤ 1 yr), early rhythm-control therapy reduced CV death, stroke or hospitalisation for HF or ACS versus usual care.HR 0.79Read →
- 2019CABANACardiology · AF · AblationIn 2,204 patients with symptomatic atrial fibrillation, catheter ablation did not significantly reduce death, disabling stroke, serious bleeding, or cardiac arrest compared with antiarrhythmic drug therapy.HR 0.8695% CI 0.65-1.15Read →
- 2018CASTLE-AFCardiology · AF · AblationIn 363 patients with AF and heart failure with reduced ejection fraction, catheter ablation reduced death or heart-failure hospitalisation compared with medical therapy.HR 0.62Read →
- 2010RACE IICardiology · AF · rate controlIn 614 patients with permanent atrial fibrillation, lenient rate control (resting heart rate <110 bpm) was non-inferior for a composite of cardiovascular events compared with strict rate control.12.9% vs 14.9%Read →
- 2002AFFIRMCardiology · AF · Rate vs rhythmIn 4,060 patients with AF at high risk of stroke, a rhythm-control strategy did not reduce all-cause mortality compared with rate control.HR 1.1595% CI 0.99-1.34Read →
Catheter & surgical ablation2
- 2023ADVENTCardiology · AF · AblationIn 607 patients with paroxysmal AF, pulsed-field ablation was non-inferior to conventional thermal ablation for treatment success and safety.73.3% vs 71.3%Read →
- 2020PRAGUE-17Cardiology · AF · LAAOIn 402 high-risk patients with non-valvular atrial fibrillation, percutaneous left atrial appendage closure was non-inferior for a composite of cardiovascular and bleeding events compared with direct oral anticoagulants.HR 0.8495% CI 0.53-1.31Read →
Left atrial appendage occlusion2
- 2021LAAOS IIICardiology · AF · surgical LAAOIn 4,660 patients with atrial fibrillation undergoing cardiac surgery, surgical left atrial appendage occlusion reduced ischaemic stroke or systemic embolism compared with no occlusion.HR 0.6795% CI 0.53-0.85Read →
- 2014PROTECT AFCardiology · AF · LAAOIn 707 patients with non-valvular atrial fibrillation eligible for warfarin, Watchman left atrial appendage closure was non-inferior for stroke, systemic embolism, or cardiovascular death compared with warfarin.IRR 0.6095% CI 0.41-1.05Read →
Device-detected / subclinical AF3
- 2024ARTESiACardiology · AF · DOACIn 4,012 patients with device-detected subclinical AF and stroke risk factors, apixaban reduced stroke or systemic embolism compared with aspirin, at the cost of more bleeding.HR 0.6395% CI 0.45-0.88Read →
- 2023NOAH-AFNET 6Cardiology · AF · DOACIn 2,536 patients with device-detected atrial high-rate episodes, edoxaban did not reduce cardiovascular death, stroke, or systemic embolism compared with placebo.HR 0.8195% CI 0.60-1.08Read →
- 2014CRYSTAL AFCardiology · AF · cardiac monitorIn 441 patients with recent cryptogenic stroke, an insertable cardiac monitor detected atrial fibrillation more often than conventional follow-up.HR 6.495% CI 1.9-21.7Read →
Published since the guideline1
- 2025OPTIONCardiology · AF · LAAOIn 1,600 patients with atrial fibrillation who underwent catheter ablation, left atrial appendage closure was non-inferior for death, stroke, or systemic embolism and reduced bleeding compared with oral anticoagulation.5.3% vs 5.8%Read →
Cited landmark trials not yet in the register3
Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.
- 2011AVERROES
Apixaban vs. aspirin in AF patients unsuitable for VKA.
- 2006ACTIVE-W
Oral anticoagulation superior to aspirin + clopidogrel in AF.
- 2023CASTLE-HTx
Catheter ablation in AF with end-stage heart failure.
Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.